Discovery of Novel Pharmacotherapies: Cocaine Dependence

Information

  • Research Project
  • 7186667
  • ApplicationId
    7186667
  • Core Project Number
    R01DA011542
  • Full Project Number
    5R01DA011542-09
  • Serial Number
    11542
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/30/1997 - 27 years ago
  • Project End Date
    2/28/2009 - 15 years ago
  • Program Officer Name
    SHIH, MING L
  • Budget Start Date
    3/1/2007 - 17 years ago
  • Budget End Date
    2/29/2008 - 16 years ago
  • Fiscal Year
    2007
  • Support Year
    9
  • Suffix
  • Award Notice Date
    3/7/2007 - 17 years ago
Organizations

Discovery of Novel Pharmacotherapies: Cocaine Dependence

DESCRIPTION (provided by applicant): Cocaine dependence is a problem of national significance. In the past decade there has been a considerable advance in the understanding of the chemistry and pharmacology of cocaine dependence. Notwithstanding, no cocaine pharmacotherapy has yet been approved by the FDA. A number of lead compounds are undergoing pharmacological evaluation as potential therapeutic agents. Cocaine's reinforcing properties and stimulant effects are associated with its propensity to bind to monoamine transporters. The goal of this project is to design potential pharmacotherapies for cocaine dependence. We will focus on the development of an understanding of the interaction between ligand and monoamine neurotransmitter uptake systems. We propose to expand our search for compounds that bind to DAT and SERT mechanisms but disturb dopamine (DA) uptake minimally, for compounds with slow onset and long duration of action, and for mechanism-based inhibitors of cocaine binding. We will focus on three classes: 8-oxabicyclo[3,2,1]octanes (oxatropanes), 8-azabicyclo[3,2,1]octanes (tropanes) and pyrovalerone analogues. The Specific Aims are: Synthesis and evaluation of (i) non-nitrogen tropane analogs, (ii) 6- and 7 hydroxylated 8-azatropane prodrugs, (iii) 6- and 7-hydroxylated 8-oxatropan(en)es, (iv) dopamine sparing cocaine antagonists that bind irreversibly to the cocaine site, (v) 3-heterobiaryltropanes. (vi) analogues of pyrovalerone.

IC Name
NATIONAL INSTITUTE ON DRUG ABUSE
  • Activity
    R01
  • Administering IC
    DA
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    387569
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    279
  • Ed Inst. Type
  • Funding ICs
    NIDA:387569\
  • Funding Mechanism
  • Study Section
    NIDA
  • Study Section Name
    Neuropharmacology Research Subcommittee
  • Organization Name
    ORGANIX, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    WOBURN
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    01801
  • Organization District
    UNITED STATES